Healthy Volunteer Clinical Trial
Official title:
A Phase IIIb Randomized Open-label Study of Nirsevimab (Versus no Intervention) in Preventing Hospitalizations Due to Respiratory Syncytial Virus in Infants (HARMONIE)
| Verified date | April 2024 |
| Source | Sanofi |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
The purpose of this study is to determine the efficacy and safety of a single intramuscular (IM) dose of nirsevimab, compared to no intervention, for the prevention of hospitalizations due to lower respiratory tract infection (LRTI) caused by confirmed RSV infection (henceforth referred to as RSV LRTI hospitalizations) in all infants under 12 months of age who are not eligible to receive palivizumab. The visit frequency will be 1 in-person dosing/randomization visit, with monthly safety follow-up electronic contacts through the first 6 months post dosing/randomization for all participants. The study will also include a 12-month (Day 366) follow-up telephone call. The D366 follow-up telephone call will be the final follow-up telephone call for France, Germany and UK non-reconsented participants. The study will include an 18-month (D546) and a 24-month (D731, final telephone call) follow-up telephone call for UK reconsented participants.
| Status | Active, not recruiting |
| Enrollment | 8058 |
| Est. completion date | March 14, 2025 |
| Est. primary completion date | March 27, 2024 |
| Accepts healthy volunteers | Accepts Healthy Volunteers |
| Gender | All |
| Age group | 0 Days to 12 Months |
| Eligibility | Inclusion Criteria: - Born at = 29 weeks gestational age and aged 0 to 12 months (calendar age), who are entering their first RSV season on the day of inclusion in the study (D01) - Informed consent form has been signed and dated by the parent(s) or other LAR(s) (and by an independent witness if required by local regulations) - Participant and parent/LAR are able to attend the scheduled visit and to comply with all study procedures Exclusion Criteria: - Participants are not eligible for the study if any of the following criteria are met: - Known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy, such as anti-cancer chemotherapy or radiation therapy, within the preceding 6 months; or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months) - Active confirmed RSV infection at the time of dosing/randomization - Active LRTI at the time of dosing/randomization - Known systemic hypersensitivity to any of the study intervention components, or history of a life-threatening reaction to the study intervention used in the study or to a product containing any of the same substances - Laboratory confirmed thrombocytopenia, or known thrombocytopenia, as reported by the parent/LAR, contraindicating intramuscular injection - Bleeding disorder, or receipt of anticoagulants in the 3 weeks preceding inclusion, contraindicating intramuscular injection - Any condition that, in the opinion of the investigator, is at a stage where it might interfere with study conduct or completion - Moderate or severe acute illness/infection (according to investigator judgment) or febrile illness (temperature = 38.0°C [= 100.4°F]) on the day of study intervention administration. - A prospective participant should not be included in the study until the condition has resolved or the febrile event has subsided - Mother of the infant participant was administered an RSV vaccine during her pregnancy with the infant participant - Receipt of any monoclonal antibody by the infant participant - Receipt of immune globulins, blood or blood-derived products in the past 3 months by the infant participant - Participation at the time of study enrollment or planned participation during the present study period in another clinical study investigating a vaccine, drug, medical device, or medical procedure - Eligible to receive palivizumab at time of inclusion (as per local guidelines) - In an emergency setting or hospitalized involuntarily - Identified as a natural or adopted child of the Investigator or employee with direct involvement in the proposed study The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial. |
| Country | Name | City | State |
|---|---|---|---|
| France | Investigational Site 2500041 | Aix-en-Provence | |
| France | Investigational Site 2500002 | Amiens | |
| France | Investigational Site Number: 2500014 | Bordeaux | |
| France | Investigational Site 2500007 | Brest | |
| France | Investigational Site Number: 2500038 | Brest | |
| France | Investigational Site Number: 2500045 | Brest | |
| France | Investigational Site Number: 2500019 | Bron | |
| France | Investigational Site Number: 2500043 | Brumath | |
| France | Investigational Site Number: 2500001 | Caen | |
| France | Investigational Site Number: 2500032 | Chambery | |
| France | Investigational Site Number: 2500057 | Clamart | |
| France | Investigational Site Number: 2500065 | Clamart | |
| France | Investigational Site Number: 2500029 | Combs-la-Ville | |
| France | Investigational Site Number: 2500013 | Corbeil-Essonnes | |
| France | Investigational Site Number: 2500054 | Creil | |
| France | Investigational Site Number: 2500006 | Creteil | |
| France | Investigational Site Number: 2500039 | Creteil | |
| France | Investigational Site Number: 2500023 | Dijon | |
| France | Investigational Site Number: 2500069 | Draguignan | |
| France | Investigational Site 2500008 | Essey-lès-Nancy | |
| France | Investigational Site 2500030 | Étampes | |
| France | Investigational Site Number: 2500058 | Frouard | |
| France | Investigational Site Number: 2500064 | Grasse | |
| France | Investigational Site Number: 2500004 | Grenoble | |
| France | Investigational Site Number: 2500027 | Hery-Sur-Alby | |
| France | Investigational Site Number: 2500060 | Huningue | |
| France | Investigational Site 2500059 | La Garenne-Colombes | |
| France | Investigational Site Number: 2500071 | La Teste-de-Buch | |
| France | Investigational Site Number: 2500034 | Le Kremlin-Bicêtre | |
| France | Investigational Site Number: 2500072 | Libourne | |
| France | Investigational Site 2500005 | Lille | |
| France | Investigational Site 2500046 | Lille | |
| France | Investigational Site Number: 2500012 | Limoges | |
| France | Investigational Site Number: 2500037 | Longjumeau | |
| France | Investigational Site 2500021 | Maromme | |
| France | Investigational Site Number: 2500003 | Marseille | |
| France | Investigational Site Number: 2500073 | Marseille | |
| France | Investigational Site Number: 2500068 | Mont-de-Marsan | |
| France | Investigational Site Number: 2500066 | Mont-Saint-Aignan | |
| France | Investigational Site Number: 2500067 | Montpellier | |
| France | Investigational Site Number: 2500077 | Morlaix | |
| France | Investigational Site Number: 2500047 | Nantes | |
| France | Investigational Site Number: 2500009 | Nice | |
| France | Investigational Site Number: 2500055 | Nice | |
| France | Investigational Site Number: 2500040 | Nogent-sur-Marne | |
| France | Investigational Site Number: 2500022 | Orleans | |
| France | Investigational Site Number: 2500050 | Orleans | |
| France | Investigational Site Number: 2500010 | Paris | |
| France | Investigational Site Number: 2500024 | Paris | |
| France | Investigational Site Number: 2500051 | Paris | |
| France | Investigational Site Number: 2500075 | Paris | |
| France | Investigational Site Number: | Pau | |
| France | Investigational Site Number: 2500018 | Poissy | |
| France | Investigational Site Number: 2500026 | Puteaux | |
| France | Investigational Site Number: 2500042 | Rouen | |
| France | Investigational Site Number: 2500078 | Saint-Doulchard | |
| France | Investigational Site Number: 2500074 | Saint-Julien-en-Genevois | |
| France | Investigational Site Number: 2500044 | Saint-Maur-des-Fossés | |
| France | Investigational Site 2500020 | Saint-Sébastien-sur-Loire | |
| France | Investigational Site Number: 2500052 | Saverne | |
| France | Investigational Site Number: 2500015 | Toulouse | |
| France | Investigational Site Number: 2500035 | Tours | |
| France | Investigational Site Number: 2500049 | Vendenheim | |
| France | Investigational Site Number: 2500011 | Villeneuve-lès-Avignon | |
| France | Investigational Site Number: 2500063 | Villeneuve-Saint-Georges | |
| France | Investigational Site 2500028 | Vincennes | |
| Germany | Investigational Site Number: 2760036 | Augsburg | |
| Germany | Investigational Site Number: 2760017 | Bad Wildungen | |
| Germany | Investigational Site Number: 2760056 | Berlin | |
| Germany | Investigational Site Number: 2760076 | Berlin | |
| Germany | Investigational Site Number: 2760099 | Berlin | |
| Germany | Investigational Site Number: 2760050 | Bielefeld | |
| Germany | Investigational Site Number: 2760064 | Bocholt | |
| Germany | Investigational Site Number: 2760098 | Bochum | |
| Germany | Investigational Site Number: 2760040 | Bonn | |
| Germany | Investigational Site Number: 2760025 | Bramsche | |
| Germany | Investigational Site Number: 2760018 | Braunschweig | |
| Germany | Investigational Site Number: 2760051 | Detmold | |
| Germany | Investigational Site Number: 2760085 | Dortmund | |
| Germany | Investigational Site Number: 2760101 | Dusseldorf | |
| Germany | Investigational Site Number: 2760059 | Düsseldorf | |
| Germany | Investigational Site Number: 2760081 | Eckental | |
| Germany | Investigational Site Number: 2760045 | Erfurt | |
| Germany | Investigational Site Number: 2760047 | Forchheim | |
| Germany | Investigational Site Number: 2760030 | Frankfurt/Oder | |
| Germany | Investigational Site Number: 2760015 | Freiburg I. Breisgau | |
| Germany | Investigational Site Number: 2760079 | Gera | |
| Germany | Investigational Site Number: 2760005 | Gilching | |
| Germany | Investigational Site Number: 2760016 | Göttingen | |
| Germany | Investigational Site Number: 2760060 | Göttingen | |
| Germany | Investigational Site Number: 2760033 | Hamburg | |
| Germany | Investigational Site Number: 2760057 | Hamburg | |
| Germany | Investigational Site Number: 2760096 | Hamburg | |
| Germany | Investigational Site Number: 2760032 | Hamm | |
| Germany | Investigational Site Number: 2760007 | Hannover | |
| Germany | Investigational Site Number: 2760049 | Heidelberg | |
| Germany | Investigational Site Number: 2760008 | Herford | |
| Germany | Investigational Site 2760010 | Hürth | |
| Germany | Investigational Site Number: 2760091 | Hürth | |
| Germany | Investigational Site Number: 2760035 | Itzehoe | |
| Germany | Investigational Site Number: 2760095 | Kassel | |
| Germany | Investigational Site Number: 2760084 | Kirchen | |
| Germany | Investigational Site Number: 2760065 | Krefeld | |
| Germany | Investigational Site Number: 2760013 | Leipzig | |
| Germany | Investigational Site Number: 2760020 | Leipzig | |
| Germany | Investigational Site 2760006 | Mainz | |
| Germany | Investigational Site Number: 2760086 | Mainz | |
| Germany | Investigational Site Number: 2760014 | Mannheim | |
| Germany | Investigational Site Number: 2760023 | Mönchengladbach | |
| Germany | Investigational Site Number: 2760054 | Mönchengladbach | |
| Germany | Investigational Site Number: 2760046 | Munchen | |
| Germany | Investigational Site Number: 2760019 | München | |
| Germany | Investigational Site Number: 2760034 | München | |
| Germany | Investigational Site Number: 2760038 | München | |
| Germany | Investigational Site Number: 2760061 | München | |
| Germany | Investigational Site Number: 2760094 | München | |
| Germany | Investigational Site Number: 2760083 | Münster | |
| Germany | Investigational Site Number: 2760027 | Neuss | |
| Germany | Investigational Site Number: 2760004 | Niedernhausen | |
| Germany | Investigational Site Number: 2760071 | Passau | |
| Germany | Investigational Site Number: 2760001 | Regensburg | |
| Germany | Investigational Site Number: 2760003 | Rosenheim | |
| Germany | Investigational Site Number: 2760062 | Rüsselsheim A. Main | |
| Germany | Investigational Site Number: 2760092 | Saarbrücken | |
| Germany | Investigational Site 2760029 | Schönau | |
| Germany | Investigational Site Number: 2760044 | Schweigen | |
| Germany | Investigational Site Number: 2760069 | Suhl | |
| Germany | Investigational Site Number: 2760067 | Tuttlingen | |
| Germany | Investigational Site Number: 2760043 | Weiden | |
| Germany | Investigational Site Number: 2760002 | Wesel | |
| Germany | Investigational Site Number: 2760028 | Wolfsburg | |
| Germany | Investigational Site Number: 2760093 | Wolfsburg | |
| United Kingdom | Investigational Site Number: 8260007 | Amersham | |
| United Kingdom | Investigational Site Number: 8260096 | Ashford | |
| United Kingdom | Investigational Site Number: 8260053 | Banbury | |
| United Kingdom | Investigational Site Number: 8260057 | Barnet | |
| United Kingdom | Investigational Site Number: 8260004 | Barnsley | |
| United Kingdom | Investigational Site Number: 8260107 | Basildon | |
| United Kingdom | Investigational Site Number: 8260110 | Basingstoke | |
| United Kingdom | Investigational Site 8260009 | Bath | |
| United Kingdom | Investigational Site Number: 8260067 | Bath | |
| United Kingdom | Investigational Site Number: 8260100 | Bebington | |
| United Kingdom | Investigational Site Number: 8260073 | Belfast | |
| United Kingdom | Investigational Site Number: 8260095 | Bicester | |
| United Kingdom | Investigational Site Number: 8260029 | Blackburn | |
| United Kingdom | Investigational Site Number: 8260108 | Bollington | |
| United Kingdom | Investigational Site Number: 8260085 | Bolton | |
| United Kingdom | Investigational Site Number: 8260013 | Bradford | |
| United Kingdom | Investigational Site Number: 8260112 | Brierley Hill | |
| United Kingdom | Investigational Site Number: 8260058 | Brighton | |
| United Kingdom | Investigational Site 8260046 | Bristol | |
| United Kingdom | Investigational Site Number: 8260008 | Bristol | |
| United Kingdom | Investigational Site Number: 8260019 | Bristol | |
| United Kingdom | Investigational Site Number: 8260063 | Bury St. Edmunds | |
| United Kingdom | Investigational Site Number: 8260040 | Cardiff | |
| United Kingdom | Investigational Site Number: 8260062 | Cheltenham | |
| United Kingdom | Investigational Site Number: 8260066 | Chertsey | |
| United Kingdom | Investigational Site Number: 8260061 | Chippenham | |
| United Kingdom | Investigational Site Number: 8260036 | Corby | |
| United Kingdom | Investigational Site Number: 8260054 | Cottingham | |
| United Kingdom | Investigational Site Number: 8260035 | Darlington | |
| United Kingdom | Investigational Site Number: 8260037 | Darlington | |
| United Kingdom | Investigational Site Number: 8260041 | Darlington | |
| United Kingdom | Investigational Site 8260064 | Dorchester | |
| United Kingdom | Investigational Site Number: 8260087 | Dundee | |
| United Kingdom | Investigational Site 8260018 | Exeter | |
| United Kingdom | Investigational Site Number: 8260020 | Gillingham | |
| United Kingdom | Investigational Site Number: 8260056 | Great Yarmouth | |
| United Kingdom | Investigational Site Number: 8260069 | Harrow | |
| United Kingdom | Investigational Site Number: 8260109 | Highcliffe | |
| United Kingdom | Investigational Site Number: 8260101 | Ipswich | |
| United Kingdom | Investigational Site Number: 8260027 | Leicester | |
| United Kingdom | Investigational Site Number: 8260074 | Leicester | |
| United Kingdom | Investigational Site Number: 8260091 | Leicester | |
| United Kingdom | Investigational Site Number: 8260088 | Liskeard | |
| United Kingdom | Investigational Site Number: 8260030 | Liverpool | |
| United Kingdom | Investigational Site Number: 8260092 | Liverpool | |
| United Kingdom | Investigational Site Number: 8260001 | London | |
| United Kingdom | Investigational Site Number: 8260002 | London | |
| United Kingdom | Investigational Site Number: 8260010 | London | |
| United Kingdom | Investigational Site Number: 8260011 | London | |
| United Kingdom | Investigational Site Number: 8260039 | London | |
| United Kingdom | Investigational Site Number: 8260075 | London | |
| United Kingdom | Investigational Site Number: 8260076 | London | |
| United Kingdom | Investigational Site Number: 8260077 | London | |
| United Kingdom | Investigational Site Number: 8260078 | London | |
| United Kingdom | Investigational Site Number: 8260079 | London | |
| United Kingdom | Investigational Site Number: 8260084 | London | |
| United Kingdom | Investigational Site Number: 8260071 | Macclesfield | |
| United Kingdom | Investigational Site Number: 8260015 | Manchester | |
| United Kingdom | Investigational Site Number: 8260097 | Margate | |
| United Kingdom | Investigational Site Number: 8260012 | Middlesbrough | |
| United Kingdom | Investigational Site Number: 8260042 | Milton Keynes | |
| United Kingdom | Investigational Site Number: 8260072 | Nantwich | |
| United Kingdom | Investigational Site Number: 8260044 | Newcastle Upon Tyne | |
| United Kingdom | Investigational Site Number: 8260119 | Newport | |
| United Kingdom | Investigational Site Number: 8260045 | Newquay | |
| United Kingdom | Investigational Site Number: 8260024 | Norwich | |
| United Kingdom | Investigational Site 8260028 | Nottingham | |
| United Kingdom | Investigational Site 8260043 | Nottingham | |
| United Kingdom | Investigational Site Number: 8260003 | Oxford | |
| United Kingdom | Investigational Site Number: 8260022 | Oxford | |
| United Kingdom | Investigational Site Number: 8260080 | Penzance | |
| United Kingdom | Investigational Site Number: 8260093 | Peterborough | |
| United Kingdom | Investigational Site Number: 8260081 | Plymouth | |
| United Kingdom | Investigational Site 8260005 | Poole | |
| United Kingdom | Investigational Site Number: 8260094 | Poole | |
| United Kingdom | Investigational Site Number: 8260065 | Portsmouth | |
| United Kingdom | Investigational Site Number: 8260106 | Prescot | |
| United Kingdom | Investigational Site Number: 8260117 | Preston | |
| United Kingdom | Investigational Site Number: 8260016 | Reading | |
| United Kingdom | Investigational Site Number: 8260086 | Reading | |
| United Kingdom | Investigational Site Number: 8260103 | Redhill | |
| United Kingdom | Investigational Site Number: 8260105 | Redruth | |
| United Kingdom | Investigational Site 8260026 | Romsey | |
| United Kingdom | Investigational Site Number: 8260068 | Runcorn | |
| United Kingdom | Investigational Site Number: 8260059 | Salford | |
| United Kingdom | Investigational Site Number: 8260111 | Salisbury | |
| United Kingdom | Investigational Site Number: 8260014 | Sheffield | |
| United Kingdom | Investigational Site 8260051 | Southampton | |
| United Kingdom | Investigational Site Number: 8260038 | Stevenage | |
| United Kingdom | Investigational Site Number: 8260034 | Stockport | |
| United Kingdom | Investigational Site Number: 8260025 | Stockton-on-Tees | |
| United Kingdom | Investigational Site Number: 8260052 | Sunderland | |
| United Kingdom | Investigational Site Number: 8260098 | Sutton In Ashfield | |
| United Kingdom | Investigational Site Number: 8260083 | Swanage | |
| United Kingdom | Investigational Site Number: 8260047 | Swindon | |
| United Kingdom | Investigational Site Number: 8260115 | Swinton | |
| United Kingdom | Investigational Site Number: 8260102 | Tameside | |
| United Kingdom | Investigational Site Number: 8260032 | Taunton | |
| United Kingdom | Investigational Site Number: 8260031 | Torpoint | |
| United Kingdom | Investigational Site 8260082 | Wantage | |
| United Kingdom | Investigational Site Number: 8260017 | Waterlooville | |
| United Kingdom | Investigational Site Number: 8260104 | Winchester | |
| United Kingdom | Investigational Site Number: 8260021 | Winscombe | |
| United Kingdom | Investigational Site Number: 8260006 | Witney | |
| United Kingdom | Investigational Site Number: 8260060 | Witney | |
| United Kingdom | Investigational Site Number: 8260050 | Yeovil | |
| United Kingdom | Investigational Site 8260023 | York | |
| United Kingdom | Investigational Site Number: 8260116 | York |
| Lead Sponsor | Collaborator |
|---|---|
| Sanofi Pasteur, a Sanofi Company | AstraZeneca |
France, Germany, United Kingdom,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Overall incidence of RSV LRTI hospitalization through the RSV season | Number of RSV LRTI hospitalization through the RSV season. | Up to 180 days post-dosing/randomization | |
| Secondary | Incidence of very severe RSV LRTI through the RSV season | Number of very severe RSV LRTI through the RSV season. Severe RSV LRTI are defined as confirmed RSV hospitalization for LRTI with an oxygen saturation (SaO2) < 90% (at any time) and oxygen supplementation. | Up to 180 days post-dosing/randomization | |
| Secondary | Incidence of hospitalization for LRTI through the RSV season in each country | Number of RSV LRTI hospitalization in each country through the RSV season. | Up to 180 days post-dosing/randomization | |
| Secondary | Overall hospitalization for allcause LRTI in all 3 countries combined throughout the RSV season | Number of RSV LRTI hospitalization in all 3 countries combined through the RSV season. | Up to 180 days post-dosing/randomization | |
| Secondary | Incidence (overall and in each country) of RSV LRTI hospitalization throughout 150 days post-dosing/randomization | Number of RSV LRTI hospitalization, overall and in each country, throughout 150 days post-dosing/randomization. | Day 151 | |
| Secondary | Incidence of very severe RSV LRTI in all 3 countries combined through 150 days post-dosing/randomization | Number of very severe RSV LRTI in all 3 countries combined through 151 days post-dosing/randomization.
Severe RSV LRTI are defined as confirmed RSV hospitalization for LRTI with an oxygen saturation (SaO2) < 90% (at any time) and oxygen supplementation. |
Day 151 | |
| Secondary | Incidence of hospitalizations for all cause LRTI through 150 days post-dosing/randomization | Number of hospitalizations for all cause LRTI through 150 days post-dosing/randomization | Day 151 | |
| Secondary | Incidence of RSV LRTI hospitalization throughout the second year post-immunization/randomization | Number of RSV LRTI hospitalizations | Day 366 to Day 731 | |
| Secondary | Incidence of hospitalizations for all-cause LRTI throughout the second year post immunization/randomization | Number of hospitalizations for all-cause LRTI | Day 366 to Day 731 | |
| Secondary | Any immediate adverse events (AEs) reported in the 30?minutes after immunization | Number of participants experiencing immediate AEs | 30 minutes after immunization | |
| Secondary | Non-serious AEs from D01 (post-dosing/randomization) to D31 | Number of non-serious AEs | Day 01 to Day 31 | |
| Secondary | Adverse events of special interest (AESIs) from D01 visit through 1-year post-dosing/randomization or D366 | Number of participants experiencing AESIs | Day 01 through 1-year post-dosing/randomization (Day 366) | |
| Secondary | Medically attended adverse events (MAAEs) from D01 visit through 1-year post-dosing/randomization or D366 | Number of participants experiencing MAAEs | Day 01 through 1-year post-dosing/randomization (Day 366) | |
| Secondary | Serious adverse events (SAEs) from D01 visit through 1-year post-dosing/randomization or D366 | Number of participants experiencing SAEs | Day 01 through 1-year post-dosing/randomization (Day 366) | |
| Secondary | Related SAEs from D366 to D731 for United Kingdom (UK) participants | Number of UK participants experiencing SAEs related to study intervention | Day 366 to D 731 | |
| Secondary | Incidence of RSV LRTI hospitalizations through 180 days post-dosing/randomization (overall and in each country) | Number of RSV LRTI hospitalizations overall and in each country | Day 01 through 180 days post-dosing/randomization | |
| Secondary | Incidence of hospitalizations for all cause LRTI through 180 days post-dosing/randomization | Number of hospitalizations for all-cause LRTI | Day 01 through 180 days post-dosing/randomization | |
| Secondary | Incidence of RSV LRTI hospitalization from 181 days post-dosing/randomization until D366 the end of the study (overall and in each country) | Number of RSV LRTI hospitalizations overall and in each country | 181 days post-dosing/randomization until Day 366 | |
| Secondary | Incidence of hospitalizations for all cause LRTI from 181 days post-dosing/randomization until D366 | Number of hospitalizations for all-cause LRTI | 181 days post-dosing/randomization until Day 366 | |
| Secondary | Incidence of recurrent wheeze in UK reconsented participants from D01 to D731 | Number of UK reconsented participants with recurrent wheeze | Day 01 to Day 731 |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT06326723 -
Investigate the PK, Safety, and Tolerability After Single and Multiple Dose Daridorexant in Chinese Healthy Subjects
|
Phase 1 | |
| Recruiting |
NCT00001367 -
Diagnosis and History Study of Patients With Different Neurological Conditions
|
||
| Completed |
NCT02699710 -
Effect of Food, Rabeprazole, Methotrexate and Formulation on the Pharmacokinetics (PK) of GDC-0853 and the Effect of GDC-0853 on the PK of Methotrexate in Healthy Subjects
|
Phase 1 | |
| Completed |
NCT02231892 -
Repetitive Transcranial Magnetic Stimulation Equipment Testing and Pilot Study
|
N/A | |
| Not yet recruiting |
NCT06441916 -
Bioequivalence Study of Dabigatran Etexilate Capsules 150 mg in Healthy Thai Volunteers Under Fasting Conditions
|
Phase 1 | |
| Completed |
NCT03771586 -
A Study to Assess the Electrophysiology, Safety, Tolerability, and Pharmacokinetics of SAGE-718 Using a Ketamine Challenge in Healthy Subjects
|
Phase 1 | |
| Not yet recruiting |
NCT06337422 -
Bioequivalence Study of Generic Celecoxib 200 mg Capsules
|
Phase 1 | |
| Completed |
NCT03302182 -
Bioequivalence Study of Ritonavir Versus NORVIR in Healthy Chinese Subjects
|
Phase 1 | |
| Completed |
NCT05049343 -
Study of SAGE-904 Using a Ketamine Challenge to Evaluate Electrophysiology, Safety, Tolerability, and Pharmacokinetics in Healthy Participants
|
Phase 1 | |
| Recruiting |
NCT01629108 -
Normal Values in Hearing and Balance Testing
|
||
| Completed |
NCT02947854 -
Study to Assess Safety, Tolerability and Immune Response of Fimaporfin-induced Photochemical Internalisation of Antigen/Adjuvant
|
Phase 1 | |
| Completed |
NCT02534870 -
Pharmacokinetics and Safety of the Co-administration of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 in Healthy Chinese Subjects
|
Phase 1 | |
| Completed |
NCT02224053 -
Drug-Drug Interaction Study With AZD9291 and Omeprazole in Healthy Volunteers
|
Phase 1 | |
| Completed |
NCT01676584 -
A Study of Single Dose RO6811135 in Healthy Volunteers
|
Phase 1 | |
| Completed |
NCT01697436 -
A Bioequivalence Study of an Oral Solution of Copegus (Ribavirin) Compared to Copegus Tablets
|
Phase 1 | |
| Completed |
NCT01711762 -
A Pharmacokinetics Study of Radioactive-Labeled GDC-0973 in Healthy Male Volunteers
|
Phase 1 | |
| Completed |
NCT01684891 -
A 28-Day Pharmacokinetics Study of RG1662 in Healthy Male Volunteers
|
Phase 1 | |
| Completed |
NCT01433575 -
A Pharmacokinetic Study of RO4917838 in Healthy Chinese Volunteers
|
Phase 1 | |
| Completed |
NCT01591850 -
A Drug-Drug Interaction Study of Ketoconazole, Rifampicin and Ritonavir-Boosted Atazanavir With Single-Dose RO5093151 in Healthy Volunteers
|
Phase 1 | |
| Completed |
NCT02547259 -
Influence of Emotion in a Test Run Forgetfulness
|
N/A |